Esp

Esperion Therapeutics is a pharmaceutical company dedicated to developing and commercializing innovative, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The company's primary focus is on addressing the needs of patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional LDL-C lowering despite maximum tolerated statin therapy. Their lead products, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), utilize a unique mechanism of action by targeting ATP citrate lyase (ACL) to inhibit cholesterol synthesis in the liver. Esperion aims to provide accessible and effective alternatives for the millions of patients worldwide who are statin-intolerant or unable to reach their lipid goals with existing treatments.